Emmanuel Scotet

List of Publications by Year
in descending order

72	4,943	94433 37	95266 68
papers	citations	h-index	g-index

72	72	72	5048
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. Cancers, 2021, 13, 1256.	3.7	6
2	BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells. Cell Reports, 2021, 36, 109359.	6.4	44
3	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cellâ€“mediated antitumor immune response. Science Translational Medicine, 2021, 13, eabj0835.	12.4	49
4	Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma. Cell Death and Disease, 2020, 11, 19.	6.3	53
5	Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors. Immunological Reviews, 2020, 298, 117-133.	6.0	9
6	Contribution of the SYK Tyrosine kinase expression to human iNKT selfâ€reactivity. European Journal of Immunology, 2020, 50, 1454-1467.	2.9	1
7	Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells. Frontiers in Immunology, 2020, 11, 992.	4.8	6
8	Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes. , 2020, 8, e000311.		20
9	γ9δ2T cell diversity and the receptor interface with tumor cells. Journal of Clinical Investigation, 2020, 130, 4637-4651.	8.2	49
10	NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells. Clinical Cancer Research, 2019, 25, 7218-7228.	7.0	28
11	Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo. OncoImmunology, 2019, 8, e1649971.	4.6	7
12	An X-ray Vision for Phosphoantigen Recognition. Immunity, 2019, 50, 1026-1028.	14.3	7
13	IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. Journal of Immunotherapy, 2018, 41, 224-231.	2.4	14
14	Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts. Journal of Visualized Experiments, 2018, , .	0.3	2
15	Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells. Frontiers in Immunology, 2018, 9, 828.	4.8	27
16	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget, 2018, 9, 11451-11464.	1.8	46
17	Sensing of cell stress by human γδ TCR-dependent recognition of annexin A2. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3163-3168.	7.1	97
18	Butyrophilin 3A (BTN3A, CD277)â€specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation. European Journal of Immunology, 2017, 47, 982-992.	2.9	47

#	Article	IF	Citations
19	The Juxtamembrane Domain of Butyrophilin BTN3A1 Controls Phosphoantigen-Mediated Activation of Human VÎ³9VÎ´2 T Cells. Journal of Immunology, 2017, 198, 4228-4234.	0.8	36
20	Synergistic targeting of breast cancer stemâ€like cells by human Î³Î´ T cells and CD8⁺ T cells. Immunology and Cell Biology, 2017, 95, 620-629.	2.3	51
21	Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. Clinical Cancer Research, 2017, 23, 6292-6304.	7.0	69
22	Stereotaxic administrations of allogeneic human VÎ³9VÎ´2 T cells efficiently control the development of human glioblastoma brain tumors. OncoImmunology, 2016, 5, e1168554.	4.6	36
23	RhoB Mediates Phosphoantigen Recognition by VÎ³9VÎ´2ÂT Cell Receptor. Cell Reports, 2016, 15, 1973-1985.	6.4	112
24	BTN3A molecules considerably improve VÎ³9VÎ´2T cells-based immunotherapy in acute myeloid leukemia. OncoImmunology, 2016, 5, e1146843.	4.6	46
25	Molecules and Mechanisms Implicated in the Peculiar Antigenic Activation Process of Human VÃŽÂ³9VÃŽÂ´2 T Cells. Frontiers in Immunology, 2015, 5, 657.	4.8	46
26	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. Clinical Immunology, 2015, 158, 92-99.	3.2	2
27	Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-GuÃ©rin Instillations for BladderÂCancer. Clinical Genitourinary Cancer, 2015, 13, e209-e215.	1.9	8
28	Post-Transplant Cyclophosphamide (PTCY) Vs Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution. Blood, 2015, 126, 1955-1955.	1.4	0
29	VÎ³9VÎ´2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. OncoImmunology, 2014, 3, e955343.	4.6	1
30	CD1d-Restricted Antigen Presentation by VÎ³9VÎ´2-T Cells Requires Trogocytosis. Cancer Immunology Research, 2014, 2, 732-740.	3.4	19
31	The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human VÎ³9VÎ´2ÂT Cells. Immunity, 2014, 40, 490-500.	14.3	375
32	Cutting Edge: CD1d Restriction and Th1/Th2/Th17 Cytokine Secretion by Human VÎ´3 T Cells. Journal of Immunology, 2013, 191, 30-34.	0.8	130
33	Repeated Systemic Administrations of Both Aminobisphosphonates and Human VÎ³9VÎ´2 T Cells Efficiently Control Tumor Development In Vivo. Journal of Immunology, 2013, 191, 1993-2000.	0.8	51
34	Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human Î³Î´ T-cell subset. Blood, 2012, 120, 2269-2279.	1.4	443
35	The Molecular Basis for Modulation of Human VÎ³9VÎ´2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies. Journal of Biological Chemistry, 2012, 287, 32780-32790.	3.4	139
36	Full Restoration of Brucella-Infected Dendritic Cell Functionality through VÎ³9VÎ´2 T Helper Type 1 Crosstalk. PLoS ONE, 2012, 7, e43613.	2.5	13

#	Article	IF	Citations
37	A Novel HLA-B18 Restricted CD8+ T Cell Epitope Is Efficiently Cross-Presented by Dendritic Cells from Soluble Tumor Antigen. PLoS ONE, 2012, 7, e44707.	2.5	7
38	Activated iNKT cells promote VÎ³9VÎ´2-T cell anti-tumor effector functions through the production of TNF-Î±. Clinical Immunology, 2012, 142, 194-200.	3.2	16
39	Abstract 3533: Acquisition of antigen presenting cell functions by VÎ³9VÎ±2-T cells requires trogocytosis. , 2012, , .		0
40	Up-regulation of cytolytic functions of human VÎ´2â^' Î³Î´ T lymphocytes through engagement of ILT2 expressed by tumor target cells. Blood, 2011, 117, 2864-2873.	1.4	21
41	NKG2D Costimulates Human VÎ³9VÎ´2 T Cell Antitumor Cytotoxicity through Protein Kinase CÎ¸-Dependent Modulation of Early TCR-Induced Calcium and Transduction Signals. Journal of Immunology, 2010, 185, 55-63.	0.8	84
42	Human VÎ³9VÎ´2 T cells: From signals to functions. Seminars in Immunology, 2010, 22, 199-206.	5.6	45
43	Early Triggering of Exclusive IFN-Î³ Responses of Human VÎ³9VÎ´2 T Cells by TLR-Activated Myeloid and Plasmacytoid Dendritic Cells. Journal of Immunology, 2009, 183, 3625-3633.	0.8	71
44	IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human VÎ³9VÎ´2 T Cells for Adoptive Immunotherapy. Journal of Immunology, 2009, 182, 3423-3431.	0.8	61
45	Modulation of inflammation through IL-17 production by Î³Î´ T cells: Mandatory in the mouse, dispensable in humans?. Immunology Letters, 2009, 127, 8-12.	2.5	21
46	Bridging innate and adaptive immunity through gd T - dendritic cell crosstalk. Frontiers in Bioscience - Landmark, 2008, Volume, 6872.	3.0	49
47	CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood, 2007, 110, 251-258.	1.4	47
48	Self/non-self discrimination by human Î³Î´ T cells: simple solutions for a complex issue?. Immunological Reviews, 2007, 215, 123-135.	6.0	121
49	Human VÎ³9VÎ´2 T cells: promising new leads for immunotherapy of infections and tumors. Current Opinion in Immunology, 2006, 18, 539-546.	5.5	189
50	CXCR5 Identifies a Subset of VÎ³9VÎ´2 T Cells which Secrete IL-4 and IL-10 and Help B Cells for Antibody Production. Journal of Immunology, 2006, 177, 5290-5295.	0.8	133
51	Potentiation of Antigen-Stimulated VÎ³9VÎ´2 T Cell Cytokine Production by Immature Dendritic Cells (DC) and Reciprocal Effect on DC Maturation. Journal of Immunology, 2006, 176, 1386-1393.	0.8	127
52	Synergism and complementarity between human CD1 AND MHC-restricted T cells, two lymphoid subsets directed against distinct antigenic worlds. Frontiers in Bioscience - Landmark, 2005, 10, 596.	3.0	3
53	VÎ³9VÎ´2 T Cell Response to Colon Carcinoma Cells. Journal of Immunology, 2005, 175, 5481-5488.	0.8	197
54	Tumor Recognition following VÎ³9VÎ´2 T Cell Receptor Interactions with a Surface F1-ATPase-Related Structure and Apolipoprotein A-I. Immunity, 2005, 22, 71-80.	14.3	268

#	Article	IF	Citations
55	Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10685-10690.	7.1	348
56	Epsteinâ€“Barr virus and rheumatoid arthritis. Autoimmunity Reviews, 2004, 3, 362-367.	5.8	94
57	Direct killing of Epstein-Barr virus (EBV)â€“infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood, 2004, 103, 1408-1416.	1.4	69
58	+1 Frameshifting as a Novel Mechanism to Generate a Cryptic Cytotoxic T Lymphocyte Epitope Derived from Human Interleukin 10. Journal of Experimental Medicine, 2002, 195, 353-358.	8.5	46
59	Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. European Journal of Immunology, 2002, 32, 3102-3107.	2.9	50
60	Immunodominant CD8ÂT cell response to Epstein-Barr virus. Biomedicine and Pharmacotherapy, 2001, 55, 373-380.	5.6	15
61	Molecular regulation of CC-chemokine receptor 3 expression in human T helper 2 cells. Blood, 2001, 98, 2568-2570.	1.4	31
62	Frequent recognition of BCRF1, a late lytic cycle protein of Epstein-Barr virus, in the HLA-B*2705 context: evidence for a TAP-independent processing. European Journal of Immunology, 2001, 31, 708-715.	2.9	19
63	Regulation of Inhibitory and Activating Killer-Cell Ig-Like Receptor Expression Occurs in T Cells After Termination of TCR Rearrangements. Journal of Immunology, 2001, 166, 2487-2494.	0.8	78
64	A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. European Journal of Immunology, 2000, 30, 2531-2539.	2.9	84
65	Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. European Journal of Immunology, 1999, 29, 973-985.	2.9	130
66	The interplay between the duration of TCR and cytokine signaling determines T cell polarization. European Journal of Immunology, 1999, 29, 4092-4101.	2.9	169
67	The interplay between the duration of TCR and cytokine signaling determines T cell polarization. European Journal of Immunology, 1999, 29, 4092-4101.	2.9	8
68	Exon III splicing switch of fibroblast growth factor (FGF) receptor-2 and -3 can be induced by FGF-1 or FGF-2. Oncogene, 1998, 17, 67-76.	5.9	26
69	Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2. Oncogene, 1997, 14, 463-471.	5.9	22
70	T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis.. Journal of Experimental Medicine, 1996, 184, 1791-1800.	8.5	160
71	The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1264, 238-242.	2.4	42
72	ONCOPROTEIN FOS ACTIVATION IN EPITHELIAL-CELLS INDUCES AN EPITHELIOMESENCHYMAL CONVERSION AND CHANGES THE RECEPTOR ENCODED BY THE FGFR-2 MESSENGER-RNA FROM K-SAM TO BEK. Oncology Reports, 1995, 2, 203-7.	2.6	3